Arena vs Vivus: Which Obesity Stock is a Buy?
Investing is often filled with tough choices and opportunity costs. This game segment from The Motley Fool's Where The Money Is poses a hypothetical question:
Would you rather buy VIVUS (Nasdaq: VVUS) or buy Arena (NASDAQ: ARNA)?
Healthcare analysts David Williamson and Michael Douglass continue their game of "would you rather" by discussing two competing obesity drug makers struggling with lackluster sales. Watch and find out which stock David chooses and his arguments for it.
Will this stock be your next multi-bagger?
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.
The article Arena vs Vivus: Which Obesity Stock is a Buy? originally appeared on Fool.com.David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.